The influence of genetic variants on inosine-induced hyperuricaemia

The influence of genetic variants on inosine-induced hyperuricaemia in healthy adult volunteers

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12615001302549

Enrollment

100

Registered

2015-11-30

Start date

2016-02-03

Completion date

2016-08-09

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This intervention study is designed to to examine the influence of genetic variation on inosine-induced hyperuricaemia. The primary endpoint is change in serum urate over 180 minutes after inosine ingestion. Key secondary and exploratory endpoints are change in fractional excretion of urate. The key genes of interest are SLC2A9 (GLUT9) and ABCG2. However, other genes associated with purine synthesis and urate transport may also be examined in later exploratory analyses.

Interventions

Oral inosine 1.5g will be administered under direct observation on a single occasion to all participants. Participants will then be observed for three hours.

Study design

Allocation

Non-randomised trial

Primary purpose

Prevention

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

a. Able to provide written informed consent b. eGFR>60 mL/min/1.73 m2

Exclusion criteria

a. History of gout b. History of kidney stones c. History of diabetes mellitus d. Diuretic use e. Urine pH less than or equal to 5.0 (risk factor for uric acid urolithiasis)

Outcome results